
        <!DOCTYPE html>
        <html>
        <head>
            <title>OCR Results - 3102_phase2_dose_optimization.jpg</title>
            <style>
                body { font-family: Arial; margin: 20px; background: #f5f5f5; }
                .header { background: linear-gradient(135deg, #667eea, #764ba2); color: white; padding: 30px; border-radius: 10px; }
                .engine { background: white; padding: 20px; margin: 20px 0; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); }
                .metric { display: inline-block; margin: 10px 20px; }
                .metric-value { font-size: 24px; font-weight: bold; color: #667eea; }
                .text-preview { background: #f8f9fa; padding: 15px; border-radius: 5px; font-family: monospace; font-size: 12px; max-height: 200px; overflow-y: auto; }
                .winner { background: #d4f8d4; }
            </style>
        </head>
        <body>
            <div class="header">
                <h1>OCR Pipeline Results</h1>
                <p>File: 3102_phase2_dose_optimization.jpg</p>
                <p>Generated: 2025-10-31 19:30:11</p>
            </div>
        
                <div class="engine">
                    <h2>TESSERACT</h2>
                    <div class="metric">
                        <div>Words Extracted</div>
                        <div class="metric-value">3162</div>
                    </div>
                    <div class="metric">
                        <div>Processing Time</div>
                        <div class="metric-value">21.53s</div>
                    </div>
                    <div class="metric">
                        <div>Confidence</div>
                        <div class="metric-value">79.68%</div>
                    </div>
                    <h3>Text Preview:</h3>
                    <div class="text-preview">Figure 1. Study Design
7" METHODS gure 1. Study Desig
J ™
@) | NTRO D UCTI O N + This multicohort phase I/II trial, evaluated the safety and efficacy of Diseaserepeciiciechortst 2-stage expansion Dose optimization
Pe oie een  vaneonn od + Dysregulation of Enhancer of Zeste Homolog 2 (EZH2) activity cially affects cancer progression and drug resistance, especialy monotherapy in patients with ARID TAmut OCC (Cohort M2) of EC (Cohort M3)
in tumors with AT-Rich Interaction Domain 1(ARID1A) mutations (ARID1Amut)!2 the wat i Pe ; + the following three 4 Figure 1) } me | OCCC: ovarian clear cell carcinomat Stage 1: Stage 2:
* Ovarian clear cell carcinoma (OCCC) displays poorer survival rates and worse outcomes compared to other epithelial ovarian i ela rupees ane ee : One E <2 / . ; ; n=10 plus n=19 LE eo
oI oI oI A a / , , . — 350 mg continuous once daily (OD) dose in a dose expansion stage as Ys | BE: Gactenniliiel Gzvalinveni per cohort except |77 per cohort Close RP2D AUD HEE IY Dose 200 </div>
                </div>
                
                <div class="engine">
                    <h2>EASYOCR</h2>
                    <div class="metric">
                        <div>Words Extracted</div>
                        <div class="metric-value">2529</div>
                    </div>
                    <div class="metric">
                        <div>Processing Time</div>
                        <div class="metric-value">162.98s</div>
                    </div>
                    <div class="metric">
                        <div>Confidence</div>
                        <div class="metric-value">80.74%</div>
                    </div>
                    <h3>Text Preview:</h3>
                    <div class="text-preview">#3102 METHODS Figure Study Design INTRODUCTION This multicohort phase IIII trial, evaluated the safety and efficacy of Disease-specific cohorts* 2-stage expansion Dose optimization Linda R Duska | LRDSD@uvahealth org tulmimetostat. The two cohorts presented here evaluated tulmimetostat as (except cohort M4) (M2 and M3 cohort) Dysregulation of Enhancer of Zeste Homolog 2 (EZH2) activity critically affects cancer progression and drug resistance, especially monotherapy in patients with ARID Amut OCCC (Cohort M2) or EC (Cohort M3) in tumors with AT-Rich Interaction Domain I(ARIDIA) mutations (ARID Amut) ! M2 OCCC: ovarian clear cell carcinomat Stage = Stage - Stage 2a Stage 2b The patients received one of the following three doses (Figure 1): n-1O plus n=19 Ovarian clear cell carcinoma (OCCC) displays poorer survival rates and worse outcomes compared to other epithelial ovarian 350 mg continuous once (OD) dose dose M3 EC: endometria carcinomat per cohort except per cohort Close RPZD 200 mg</div>
                </div>
                </body></html>